ExPEC4V

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

ExPEC4V, also known as JNJ-63871860, is a vaccine against urinary tract infections (UTIs) and Escherichia coli infection. It is an Escherichia coli polysaccharide conjugate vaccine. The vaccine is administered by intramuscular injection. It is being developed by GlycoVaxyn and Johnson & Johnson. As of November 2023, ExPEC4V is in phase 2 clinical trials. There is also a 10-valent form called ExPEC10V (VAC-52416; JNJ-69968054). In February 2025 Johnson & Johnson stopped the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over placebo.

ExPEC4V, also known as JNJ-63871860, is a vaccine against urinary tract infections (UTIs) and Escherichia coli infection. It is an Escherichia coli polysaccharide conjugate vaccine. The vaccine is administered by intramuscular injection. It is being developed by GlycoVaxyn and Johnson & Johnson. As of November 2023, ExPEC4V is in phase 2 clinical trials. There is also a 10-valent form called ExPEC10V (VAC-52416; JNJ-69968054). In February 2025 Johnson & Johnson stopped the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over placebo.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1353358360 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.